TBX-3400

Taiga Biotechnologies, Inc. · Phase 1 active Biologic

At a glance

Generic name	TBX-3400
Sponsor	Taiga Biotechnologies, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (PHASE1)
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TBX-3400 CI brief — competitive landscape report
TBX-3400 updates RSS · CI watch RSS
Taiga Biotechnologies, Inc. portfolio CI